RFG
AZN icon

REAP Financial Group’s AstraZeneca AZN Stock Holding History

REAP Financial Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-73
Closed -$10.7K – 507
2025
Q1 		$10.7K Buy
73
+72
+7,200% +$10.4K ﹤0.01% 366
2024
Q4 		$33 Sell
1
-37
-97% -$5.18K ﹤0.01% 629
2024
Q3 		$5.92K Buy
+38
New +$6.13K ﹤0.01% 428
2024
Q1 		– Sell
-10
Closed -$1.28K – 597
2023
Q4 		$1.28K Buy
+10
New +$1.3K ﹤0.01% 577

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

REAP Financial Group's AZN Position: Q2 2025 in Review

REAP Financial Group sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 73 shares — an estimated $10.7K sold.

REAP Financial Group first reported a position in AZN in Q4 2023 and held it in 4 quarters. The position peaked at $10.7K in Q1 2025. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

  • REAP Financial Group reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
  • REAP Financial Group sold 73 AstraZeneca shares in Q2 2025, an estimated $10.7K.
  • REAP Financial Group first reported a position in AstraZeneca in Q4 2023 and held it in 4 quarters.
  • REAP Financial Group's AstraZeneca position peaked at $10.7K in Q1 2025.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on REAP Financial Group's 13F filing for Q2 2025, filed 23 Jul 2025.